Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Incurs Operating Loss 2 Years Running as Parkinson’s Write-Down Weighs
May 13, 2021
- Sumitomo Dainippon Sees 6.9% Sales Growth on Latuda, Diabetes Med; Name Change Announced
May 13, 2021
- Eisai Logs 58.8% Drop in Operating Profit as Merck Milestone Dips on Lenvima Miss
May 13, 2021
- Sawai Group Aims to Double Sales to 400 Billion Yen by FY2030: New Long-Term Vision
May 13, 2021
- 300 Million Yen Fine Sought for Alfresa Too, Verdict on June 30: Bid-Rigging Trial
May 13, 2021
- Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
May 12, 2021
- Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
May 12, 2021
- Ono Chief Questions Yet Another Re-Pricing for Opdivo, 11.5% Cut in August
May 12, 2021
- Fuji Yakuhin Out-Licenses Hyperuricemia Med Dotinurad to US Biotech
May 12, 2021
- Shionogi Chief Eyes Conditional Approval for COVID-19 Vaccine, Supply by Year’s End If OK’ed
May 11, 2021
- Chugai, Japan Govt Cut Supply Deal for COVID-19 Antibody Cocktail
May 11, 2021
- Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
May 11, 2021
- Shionogi Incurs Double-Digit Sales Fall in FY2020 as Infectious Disease Meds Falter
May 11, 2021
- Daiichi Sankyo’s DS-1062 Notches Positive PI Data in Triple Negative Breast Cancer
May 11, 2021
- Lawyer Hiroaki Tanaka Tapped to Lead Kobayashi Kako in Management Reshuffle
May 11, 2021
- Maruishi to Curb Supply of 5 Sedative Products due to Increase in Severe COVID-19 Cases
May 11, 2021
- Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
- Kyoto Startup to Begin Clinical Trial of iPSC-Derived Platelet Agent This Year, Eyes 10 Billion Yen Biz
May 10, 2021
- Kyowa Kirin’s Q1 Sales Rise on Strong Performance Overseas
May 10, 2021
- Positive Ruling for Shionogi Now Final and Binding: Osaka Tax Suit
May 10, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…